Enanta Pharmaceuticals, Inc. (9EP.F)

12.20 -0.70 (-5.43%) At close: 09:55PM CEST

Enanta Pharmaceuticals, Inc.

500 Arsenal Street
Watertown, MA 02472
United States
617 607 0800
https://www.enanta.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 145

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Jay R. Luly Ph.D.	President, CEO & Director	1.17M	1.9M	1956
Mr. Paul J. Mellett Jr.	Senior VP of Finance & Administration and CFO	625.04k	496.76k	1955
Dr. Yat Sun Or Ph.D.	Senior VP of Research & Development and Chief Scientific Officer	683.59k	398.22k	1952
Mr. Nathaniel S. Gardiner J.D.	Consultant	630.51k	46.06k	1954
Mr. Brendan Luu	Senior Vice President of Business Development	583.81k	N/A	1975
Ms. Jennifer Viera	Senior Director of Investor Relations & Corporate Communications	N/A	N/A	N/A
Ms. Tara Lynn Kieffer Ph.D.	Senior Vice President of New Product Strategy & Development	465.71k	N/A	1978
Dr. Scott T. Rottinghaus M.D.	Senior VP & Chief Medical Officer	578.07k	N/A	1974

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Corporate governance

Enanta Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 April 2024 is 5. The pillar scores are Audit: 3; Board: 4; Shareholder rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.